araag2/HINT huggingface dataset:
Clinical trial NCT01436110 (phase 3, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: fluticasone furoate 50mcg, fluticasone propionate 100mcg, placebo
SMILES: [H][C@@]12C[C@@H](C)[C@](OC(=O)C3=CC=CO3)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C, [H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Signed informed consent

          -  Outpatient at least 12 years of age with a diagnosis of asthma at least 12 weeks prior
             to first visit

          -  Both genders; females of child bearing potential must be willing to use appropriate
             contraception during the study

          -  Pre-bronchodilator FEV1 of at least 60% predicted

          -  FEV1 reversibility of at least 12% and 200ml

          -  Current asthma therapy that includes a non-corticosteroid controller and/or short
             acting beta-agonist

        Exclusion Criteria:

          -  History of life-threatening asthma exacerbation with the past 10 years

          -  Asthma exacerbation requiring oral corticosteroids within the past 3 months or
             overnight hospital stay within the past 6 months

          -  Current or recent respiratory infection or current oral candida infection

          -  Presence of a significant respiratory disease or other medical condition that is
             uncontrolled or that could affect subject safety or study outcome

          -  Known or suspected allergy to study medication or materials

          -  Taking another investigational medication or prohibited medication during the study

          -  Current smokers or former smokers with significant tobacco exposure

          -  Previous treatment with fluticasone furoate in a phase II or III study

          -  Children in Care
Clinical trial NCT00273871 (phase 3, status: completed)
Conditions: graft rejection, kidney failure, kidney transplantation
ICD codes: T86.830, T86.820, N19, T86.12, N17.8, N17.9, O90.4, N99.0, N17.0, N26.2, Q63.0, Q63.2, Z52.4, I75.81, N19, N20.0
Drugs: cyclosporin or tacrolimus
SMILES: CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
Eligibility criteria:

        Inclusion Criteria:

          -  Age over 18

          -  Treatment with a calcineurin inhibitor

          -  Patients with mild to moderate renal insufficiency

        Exclusion Criteria:

          -  Patients with acute rejection

          -  Patients who received a transplant more than 10 years ago
Clinical trial NCT00373425 (phase 3, status: completed)
Conditions: non-small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: erlotinib, placebo
SMILES: COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Primary tissue from patient's surgery must be epidermal growth factor receptor
             (EGFR)-positive by certain tests

          -  Patients may have up to 4 cycles of chemotherapy after surgery

          -  Complete removal of the tumor by surgery

          -  Able to start drug under the following timelines:

               -  6 months from the day of surgery for patients who get chemotherapy

               -  3 months from the day of surgery for those who do not get chemotherapy

          -  Confirmed diagnosis of Stage IB-IIIA NSCLC

          -  Patients must be accessible for follow-up visits

        Exclusion Criteria:

          -  History of prior radiotherapy for NSCLC either before or after surgery

          -  History of heart disease or uncontrolled heart arrhythmias within the previous year

          -  History of poorly controlled gastrointestinal (GI) disorders that could affect the
             absorption of study drug

          -  History of other cancer except certain skin or cervical cancers, patients who have had
             other cancer are eligible if they have remained disease free for at least 5 years

          -  Patients who have received chemotherapy for NSCLC before surgery

          -  Tumors with mixed histology of NSCLC and Small Cell Lung Cancer (SCLC). Patients with
             carcinoid tumors are not eligible.
Clinical trial NCT01209689 (phase 3, status: terminated)
Conditions: spondylitis, ankylosing
ICD codes: M08.1, M45.6, M45.2, M45.3, M45.4, M45.5, M45.7
Drugs: tocilizumab, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    clinical development program terminated due to failure to achieve efficacy
  
Eligibility criteria:

        Inclusion Criteria:

          -  Adult patients ≥ 18 years of age.

          -  Ankylosing spondylitis as defined by the modified New York criteria for ≥ 3 months
             prior to baseline.

          -  Active disease at screening and baseline (Bath Ankylosing Spondylitis Disease Activity
             Index [BASDAI] ≥ 4.0, spinal pain visual analog scale [VAS] ≥ 40).

          -  Inadequate response or intolerant to 1 or more previous non-steroidal
             anti-inflammatory drugs (NSAIDs).

          -  Inadequate response to treatment with etanercept, infliximab, adalimumab, or golimumab
             because of inadequate efficacy.

          -  Tumor necrosis factor (TNF) antagonist therapy must have been discontinued at least 8
             weeks prior to baseline (etanercept 4 weeks).

          -  Traditional disease-modifying anti-rheumatic drugs (DMARDs) must be withdrawn for at
             least 4 weeks prior to baseline (methotrexate, sulfasalazine, and hydroxychloroquine
             or chloroquine may be allowed if at stable dose for at least 4 weeks prior to
             baseline).

          -  Oral corticosteroids (≥ 10 mg/day prednisone or equivalent) and
             NSAIDs/cyclooxygenase-2 [COX-2] inhibitors must be at stable dose for at least 4 weeks
             prior to baseline.

        Exclusion Criteria:

          -  Major surgery (including joint surgery) within 8 weeks prior to screening or planned
             major surgery within 6 months after randomization.

          -  Total ankylosis of spine (as determined by investigator).

          -  Inflammatory rheumatic disease other than ankylosing spondylitis.

          -  Active, acute uveitis at baseline.

          -  Previous treatment with tocilizumab.

          -  Intra-articular or tendon injections or parenteral corticosteroids within 4 weeks
             prior to screening.

          -  History of severe allergic or anaphylactic reactions to humanized or murine monoclonal
             antibodies.

          -  Active current or history of recurrent bacterial, viral, fungal, mycobacterial, or
             other infection.

          -  History of or currently active primary or secondary immunodeficiency.

          -  Body weight > 150 kg.
Clinical trial NCT00159887 (phase 3, status: completed)
Conditions: pulmonary hypertension
ICD codes: I27.0, I27.20, I27.21, I27.24, I27.29, P29.30, I27.22
Drugs: sildenafil citrate
SMILES: CCCC1=NN(C)C2=C1NC(=NC2=O)C1=C(OCC)C=CC(=C1)S(=O)(=O)N1CCN(C)CC1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with PAH who had completed the 12 week pivotal study

        Exclusion Criteria:

          -  Any other patients with PAH that had not been included into the pivotal study
Clinical trial NCT01451203 (phase 3, status: completed)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: placebo, czp, methotrexate (mtx)
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects with RA as defined by the ACR/EULAR criteria (2010) who meet all of the
             following criteria:

               1. Subjects who developed RA within one year after onset of RA.

               2. Subjects who have never received MTX before (MTX naive)

               3. Subjects whose disease activity is moderate or higher (DAS28(ESR) ≥ 3.2）

               4. Subjects must satisfy at least two of the three criteria (Anti-CCP antibody
                  positive, Rheumatoid factor positive, Presence of X-ray erosion） for poor
                  prognostic factors. The anti-CCP antibody positive is essential for every
                  patient.

        Exclusion Criteria:

          -  Patients who have a diagnosis of any other type of inflammatory arthritis.

          -  Patients who have a secondary, non-inflammatory type of arthritis.

          -  Patients who have used with MTX, reflunomide, or any other biologics prior to the
             start of study drug administration.

          -  Patients who have NYHA (New York Heart Association) Class III or IV congestive heart
             failure

          -  Patients who currently have, or who have a history of, tuberculosis.

          -  Patients who have a high risk of infection (with a current infectious disease, a
             chronic infectious disease, a history of serious infectious disease)

          -  Patients who currently have, or have a history of, malignant tumor

          -  Female patients who are breastfeeding or pregnant, who are of childbearing potential
Clinical trial NCT00002868 (phase 3, status: completed)
Conditions: leukemia
ICD codes: C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, C91.01
Drugs: busulfan, cytarabine, etoposide, hydroxyurea, idarubicin
SMILES: CS(=O)(=O)OCCCCOS(C)(=O)=O, ClCCN(CCCl)P1(=O)NCCCO1, OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1, NC(=O)NO, [H][C@@]12C[C@H](N(C(=O)[C@H](C)N[C@@H](CCC3=CC=CC=C3)C(=O)OCC)[C@@]1([H])CCCC2)C(O)=O
Eligibility criteria:

        DISEASE CHARACTERISTICS: Newly diagnosed chronic myelogenous leukemia in chronic phase
        Philadelphia chromosome and/or BCR/ABL positive Initial diagnosis within 6 months of
        randomization No clinical or laboratory evidence of acceleration or blastic disease No
        contraindication to peripheral blood cell stem cell collection prior to treatment

        PATIENT CHARACTERISTICS: Age: 15 to 65 Performance status: Not specified Life expectancy:
        Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified
        Other: No major organ impairment Not pregnant Fertile patients must use effective
        contraception

        PRIOR CONCURRENT THERAPY: Biologic therapy: No prior interferon alfa Chemotherapy: Prior
        hydroxyurea allowed Endocrine therapy: Not specified Radiotherapy: Not specified Surgery:
        Not specified
Clinical trial NCT00152516 (phase 3, status: completed)
Conditions: epilepsy, partial
ICD codes: G40.111, G40.119, G40.211, G40.219, G40.101, G40.109, G40.201
Drugs: levetiracetam (lev)
SMILES: CC[C@H](N1CCCC1=O)C(N)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Pediatric patients with partial onset seizures, with 1 to 2 anti-epileptic drugs
             (AEDS), with participation in previous levetiracetam pediatric studies (N01009 or
             N01103) or direct enrollment, for whom levetiracetam treatment will be of possible
             benefit

        Exclusion Criteria:

          -  Patients on a ketogenic diet

          -  Seizures too close together to accurately count

          -  Pseudoseizures

          -  Status epilepticus 1 month prior Visit 1

          -  Current diagnosis of Lennox-Gastaut Syndrome or epilepsy secondary to a progressing
             cerebral disease will be excluded from the study.
Clinical trial NCT00570986 (phase 3, status: completed)
Conditions: plaque psoriasis
ICD codes: L40.0, L40.4, L40.8, L40.9, L40.1, L40.50
Drugs: placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Subject is >= 18 years of age

          -  Subject had a clinical diagnosis of psoriasis for at least 6 months, and had moderate
             to severe plaque psoriasis

          -  Subject is judged to be in generally good health as determined by the principal
             investigator

        Exclusion Criteria:

          -  Subject has previous exposure to systemic anti-IL 12 therapy

          -  Subject cannot discontinue systemic therapies and/or topical therapies for the
             treatment of psoriasis and cannot avoid UVB or PUVA phototherapy

          -  Subject is taking or requires oral or injectible corticosteroids

          -  Subject diagnosed with erythrodermic psoriasis, pustular psoriasis, medication-induced
             or medication-exacerbated psoriasis or new onset guttate psoriasis

          -  Subject considered by the investigator, for any reason, to be an unsuitable candidate

          -  Female subject who is pregnant or breast-feeding or considering becoming pregnant
Clinical trial NCT01297920 (phase 3, status: completed)
Conditions: open-angle glaucoma, ocular hypertension
ICD codes: H40.10X0, H40.10X1, H40.10X2, H40.10X3, H40.10X4, H40.1130, H40.1131, H40.053, H40.051, H40.052, H40.059
Drugs: brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, brinzolamide ophthalmic suspension, 1%, brimonidine tartrate ophthalmic solution, 0.2%
SMILES: BrC1=C(NC2=NCCN2)C=CC2=NC=CN=C12, CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O, BrC1=C(NC2=NCCN2)C=CC2=NC=CN=C12
Eligibility criteria:

        Inclusion Criteria:

          -  Sign Informed Consent document.

          -  Diagnosis of open-angle glaucoma or ocular hypertension, with mean intraocular
             pressure within protocol-specified range at eligibility visit/s.

          -  Other protocol-specified inclusion criteria may apply.

        Exclusion Criteria:

          -  Females of childbearing potential if pregnant, lactating, or not using highly
             effective birth control measures.

          -  Any form of glaucoma other than open-angle glaucoma.

          -  Severe central vision loss in either eye.

          -  Chronic, recurrent, or severe inflammatory eye disease.

          -  Ocular trauma within the preceding 6 months.

          -  Ocular infection or ocular inflammation within the preceding 3 months.

          -  Clinically significant or progressive retinal disease such as retinal degeneration,
             diabetic retinopathy, or retinal detachment.

          -  Best-corrected visual acuity score worse than 55 letters using the Early Treatment
             Diabetic Retinopathy Study chart.

          -  Other ocular pathology (including severe dry eye) that may, in the opinion of the
             Investigator, preclude the administration of study product.

          -  Ocular surgery within the preceding 6 months.

          -  Ocular laser surgery within the preceding 3 months.

          -  Any abnormality preventing reliable applanation tonometry.

          -  Any other conditions, including severe illness, which could make the subject, in the
             opinion of the Investigator, unsuitable for the study.

          -  Other protocol-specified exclusion criteria may apply.
Clinical trial NCT01718145 (phase 3, status: completed)
Conditions: hepatitis c virus infection
ICD codes: B00.81, B25.1, B26.81, B58.1, K75.4, A51.45, B17.2
Drugs: daclatasvir, asunaprevir, ribavirin, telaprevir
SMILES: COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C1=NC=C(N1)C1=CC=C(C=C1)C1=CC=C(C=C1)C1=CN=C(N1)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C, COC1=CN=C(O[C@@H]2C[C@H](N(C2)C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)N[C@@]2(C[C@H]2C=C)C(=O)NS(=O)(=O)C2CC2)C2=C1C=CC(Cl)=C2, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, [H][C@@]12CCC[C@]1([H])[C@H](N(C2)C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C1CCCCC1)C(C)(C)C)C(=O)N[C@@H](CCC)C(=O)C(=O)NC1CC1
Eligibility criteria:

        Inclusion Criteria:

          -  Chronic HCV-1b infected patient

          -  HCV Ribonucleic acid (RNA) > 100,000 IU/mL at screening

          -  Ages 20 to 70 years (for the Naive cohort), ages 20 to 75 years (for the Relapser
             cohort)

          -  Treatment naive subjects to Interferon (IFN) based therapy

          -  Subjects who had undetectable HCV RNA at end of treatment with prior exposure to an
             IFN-containing regimen, but HCV RNA detectable within 24 weeks of treatment follow-up

        Exclusion Criteria:

          -  Patients who have;

               -  Hepatocellular carcinoma

               -  Co-infection with Hepatitis B virus (HBV) or Human immunodeficiency virus (HIV)

               -  Severe or uncontrollable complication
Clinical trial NCT00146549 (phase 3, status: completed)
Conditions: breast cancer, stage iv breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60, C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: trastuzumab, vinorelbine, paclitaxel, docetaxel
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically confirmed invasive breast cancer, with stage IV
             disease

          -  Tumors must be HER2 overexpressing

          -  Measurable disease, defined as a least one lesion that can be accurately measured in
             at least one dimension

          -  18 years of age or older

          -  Life expectancy of greater than 6 months

          -  ECOG performance status of 0-2

          -  ANC count > 1,500/mm3

          -  Platelets > 100,000/mm3

          -  Total bilirubin < 1.5 mg/dl

          -  AST/ALT < 115 U/I

          -  Creatinine < 2.0 mg/dl

          -  Glucose < 200 mg/dl

          -  LVEF > 50%

        Exclusion Criteria:

          -  Prior chemotherapy or prior trastuzumab therapy for metastatic breast cancer

          -  Concurrent hormonal therapy, chemotherapy, or radiation treatments

          -  Pregnant or lactating women

          -  Known brain metastases or leptomeningeal carcinomatosis

          -  History of grade 3 or 4 allergic reactions attributed to compounds of similar chemical
             or biologic composition to the agents in this study

          -  Pre-existing neuropathy from any cause in excess of grade 1

          -  Uncontrolled intercurrent illness

          -  History of other non-breast cancer malignancy except for carcinoma in situ of the
             cervix or non-melanoma skin cancer

          -  Patients taking macrolide antibiotics, ketoconazole, or AZT
Clinical trial NCT00262106 (phase 3, status: completed)
Conditions: hiv infections, gonorrhea, chlamydial infections, genital herpes
ICD codes: Z21, A60.02
Drugs: pro 2000/5, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Women aged 16 years and above at enrolment in Masaka and Mwanza, or aged 18 years and
             above at enrolment in the South African and Zambian sites

          -  Likely to be sexually active at entry and during follow-up

          -  Willing to undergo HIV testing at screening and approximately 12 weekly intervals, and
             additionally, if required, to determine HIV status

          -  HIV negative at screening according to the local HIV testing algorithm

          -  Willing to receive the HIV result before randomization

          -  Willing to use study gel as instructed

          -  Willing to undergo regular speculum examinations and genital infection screens

          -  Willing to have regular urine pregnancy tests

          -  Willing to receive health education about condoms

          -  Willing and able to give informed consent

        Exclusion Criteria:

          -  Unable or unwilling to provide a reliable method of contact for the field team

          -  Likely to move permanently out of the area within the next year

          -  Likely to have sex more than 14 times a week on a regular basis during the course of
             follow-up

          -  Using spermicides regularly

          -  Pregnant or within 6 weeks postpartum at enrollment

          -  Has Grade 3 clinical or laboratory abnormalities which are considered by the clinician
             or the Trial Management Group to make enrollment inadvisable

          -  Requires referral for assessment of a clinically suspicious cervical lesion

          -  Treatment to the cervix, or to the womb through the cervix, within 30 days of
             enrolment

          -  Known latex allergy

          -  Participating, or has participated within 30 days of enrolment, in a clinical trial of
             an unlicensed product, microbicide, barrier method, or any other intervention likely
             to impact on the outcome of this trial

          -  Considered unlikely to be able to comply with the protocol
Clinical trial NCT00268879 (phase 3, status: completed)
Conditions: irritable bowel syndrome
ICD codes: K58.2, K58.8, K58.0, K58.1, K58.9
Drugs: renzapride
SMILES: COC1=C(C=CC(N)=C1Cl)C(=O)NC1CCN2CCCC1C2
Eligibility criteria:

        Inclusion Criteria:

          -  Females with constipation predominant IBS as defined by the Rome II criteria

          -  Colonoscopy or sigmoidoscopy in previous 5 years showed no significant disease

        Exclusion Criteria:

          -  Patients who have diarrhoea predominant or alternating symptom IBS

          -  Other gastrointestinal diseases that affect bowel transit